

**Table. Clinical guidelines for staging bone scans**

<b>Clinical Guidelines</b>		<b>Recommend bone scan if any of these:</b>
<b>EAU</b>	European Association of Urology	<ul style="list-style-type: none"> <li>- GS <math>\geq</math>8</li> <li>- cT3/T4 disease</li> <li>- PSA &gt;10 ng/ml</li> <li>- Symptomatic</li> </ul>
<b>AUA</b>	American Urological Association	<ul style="list-style-type: none"> <li>- GS <math>\geq</math>8</li> <li>- PSA &gt;20 ng/ml</li> <li>- Symptomatic</li> </ul>
<b>NCCN</b>	National Comprehensive Cancer Network	<ul style="list-style-type: none"> <li>- cT1 disease &amp; PSA &gt;20 ng/ml</li> <li>- cT2 disease &amp; PSA &gt;10 ng/ml</li> <li>- Gleason sum <math>\geq</math>8</li> <li>- cT3/T4 disease</li> <li>- Symptomatic</li> </ul>
<b>Briganti's CART</b>	Briganti's Classification and Regression Tree	<ul style="list-style-type: none"> <li>- GS <math>\geq</math>8</li> <li>- <math>\geq</math>cT2 disease &amp; PSA &gt;10 ng/ml</li> <li>- Symptomatic</li> </ul>

## Estimating Sensitivity and Specificity of the Clinical Guidelines

We used the method outlined by Begg and Greenes<sup>1</sup> to estimate the sensitivity and specificity of the published recommendations regarding the need for staging bone scan (BS) in newly-diagnosed prostate cancer patients. We define the “test” to be the outcome of applying some guideline (G), such as the AUA guideline, where “+” and “-”, denote whether a patient is recommended to receive a BS or not, respectively. The sensitivity and specificity are defined as:

$$\text{Sensitivity} = P(G + | \text{Disease Present})$$

$$\text{Specificity} = P(G - | \text{Disease Not Present})$$

Following the approach described in Begg and Greenes<sup>1</sup> if we assume that the factors considered by the guideline (e.g. PSA, Gleason Score) are the only factors that influence selection of patients recommended for staging BS, then using *Bayes Rule* we can write:

$$\text{Sensitivity} = P(G + | \text{Disease Present}) = \frac{P(\text{Disease Present} | G+)P(G+)}{P(\text{Disease Present})}$$

$$\text{Specificity} = P(G - | \text{Disease Not Present}) = \frac{P(\text{Disease Not Present} | G-)P(G-)}{P(\text{Disease Not Present})}$$

The probabilities above were estimated as follows:

- 1) To estimate  $P(\text{Disease Present} | G+)$  and  $P(\text{Disease Not Present} | G-)$ , separate the entire population (with and without bone scan) into G- and G+ and apply the logistic regression model to get an estimate of the mean probability for each group of patients.
- 2) Estimate  $P(G+)$  and  $P(G-)$  as the proportion of the population with G+ and G-.
- 3) Estimate  $P(\text{Disease Present})$  and  $P(\text{Disease Not Present})$  based on the following:

$$\begin{aligned} P(\text{Disease Present}) \\ &= P(\text{Disease Present} | G+)P(G +) + P(\text{Disease Present} | G-)P(G -) \end{aligned}$$

$$\begin{aligned} P(\text{Disease Not Present}) \\ &= P(\text{Disease Not Present} | G+)P(G +) \\ &\quad + P(\text{Disease Not Present} | G-)P(G -) \end{aligned}$$

---

1. Begg, C. B., Greenes, R. A.: Assessment of diagnostic tests when disease verification is subject to selection bias. *Biometrics*, **39**: 207, 1983